Frank Scheffler will be attending the 33rd Medicinal Chemistry in Eastern England meeting in Hatfield on Thursday 28th April 2022.

Known colloquially as the “Hatfield MedChem” meeting, this is a long-standing, one-day meeting which runs annually.

The scientific program comprises presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemist.

Programme
9:00  Registration/Coffee

MORNING SESSION Chair: Alison Jones (Charles River)

09:30   Welcome and Introduction

09:35   The discovery of novel GPR52 agonists:  HTL0041178, a potential therapy for schizoaffective and related psychiatric disorders
Steve Watson (Heptares)

10:10  Discovery and development of first-in-class USP19 inhibitors for the treatment of metabolic and muscle-wasting disease
Shane Rountree (Almac)

10:45   Refreshments

11:10   Development and characterisation of 2-imino-hexahydropyrimidin-4-one derived Plasmepsin X inhibitors with in vivo anti-malarial activity
Teresa de Haro (UCB)

11:45   The Development of MNK Protacs
Martin Ambler (LifeArc)

12:10   Discovery and optimisation of allosteric inhibitors of Glutaminase 1 (GLS1) 
Mark Charles (Cancer Research UK)

12:35   Lunch

AFTERNOON SESSION Chair: Simon Ward (Medicines Discovery Institute, Cardiff University)

13:30   Capps Green Zomaya Award Lecture
Jeremy Besnard (Exscientia)

14:05   Development of MAP4K4 Inhibitors for the Suppression of Cardiac Muscle Cell Death
Nick Martin (Domainex)

14:40   Accelerating decision making through parallel med chem
Neal Fazakerley (GSK)

15:05     Refreshments

15:30     Next generation estrogen receptor degraders (SERDs): A decade of discovery at AstraZeneca 
Samantha Hughes (Astra Zeneca)

16:05   Discovery of novel LasB inhibitors as an inhaled antivirulence therapy for the treatment of Pseudomonas aeruginosa infections in patients with chronic respiratory disease
David Davies (Antabio)

16:30   Discovery and first disclosure of DDU209 a potent and selective inhibitor of Lysyl tRNA synthetase for Tuberculosis
Laura Cleghorn (Dundee Drug Discovery Unit, Univ Dundee)

16:55   Concluding Remarks

17:00   Meeting close